

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Oseltamivir Phosphate for Suspension (0.36g) (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Oseltamivir phosphate is a selective inhibitor of influenza virus neuraminidase, which can inhibit the release of virus from infected cells via inhibition of neuraminidase activity of influenza A and B viruses, thereby reducing the spread of influenza A or B viruses. The Product is indicated for the treatment of influenza A and B in adults and children 2 weeks of age and older, and for the prevention of influenza A and B in people 1 year of age and older.

The approval of the Product will further enrich the Group’s product portfolio in the therapeutic area of anti-infectives.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 15 April 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.